Tharimmune, Inc. (THAR)
(Delayed Data from NSDQ)
$3.00 USD
+0.10 (3.45%)
Updated Aug 15, 2024 03:59 PM ET
After-Market: $3.00 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
THAR 3.00 +0.10(3.45%)
Will THAR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for THAR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for THAR
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
THAR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for THAR
THAR Stock Earnings: Tharimmune Reported Results for Q2 2024
Tharimmune appoints David Jones to Scientific Advisory Board
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Tharimmune appoints David Clarke as strategic advisor
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor